本研究的目的是评估肺癌电视胸腔镜手术期间给予右美托咪定对围手术期炎症反应和慢性术后疼痛的影响。 队列包括 152 名计划择期电视胸腔镜手术的肺癌患者参加了这项随机对照试验。患者被随机分为 2 组，并给予等量的右美托咪定 (n = 63) 或生理盐水 (n = 63)。麻醉诱导前 10 分钟给予右美托咪定剂量 0.6 μg/kg，并维持在 0.5 μg/kg/h 直至手术完成前 0.5 小时。两组的麻醉和术后疼痛管理方案均标准化。分析包括生命体征、疼痛数值评定量表、血液炎症和氧化应激生物标志物、疼痛类型和部位、患者自控静脉镇痛的使用、全身麻醉药和止痛药物的消耗以及并发症。右美托咪定的给药结果炎症细胞因子（白细胞介素 1 β、白细胞介素 6 和肿瘤坏死因子 α）和氧化应激生物标志物（活性氧和丙二醛）水平降低，但白细胞介素 10 和超氧化物歧化酶水平升高。此外，右美托咪定组术后数字评定量表评分较低，麻醉药用量减少，胸管拔除速度更快，患者自控静脉镇痛按压次数减少，术后住院时间较短。右美托咪定的使用有效减轻了手术炎症、氧化应激和术后疼痛，从而促进肺癌手术后患者的康复，而不增加不良反应或并发症的风险。版权所有 © 2024 Elsevier Inc. 保留所有权利。

The objective of the present study was to evaluate the effect of dexmedetomidine administration during video-assisted thoracoscopic surgery for lung cancer on perioperative inflammatory response and chronic post-surgical pain.A cohort of 152 patients with lung cancer scheduled for elective video-assisted thoracoscopic surgery participated in this randomized controlled trial. Patients were randomly divided into 2 groups and administered an equivalent volume of dexmedetomidine (n = 63) or normal saline (n = 63). Dexmedetomidine was administered at a dose of 0.6 μg/kg 10 minutes before anesthesia induction and maintained at 0.5 μg/kg/h until 0.5 hours before surgery completed. Anesthesia and postoperative pain management protocols were standardized for both groups. The analysis included vital signs, numerical rating scales of pain, blood inflammatory and oxidative stress biomarkers, pain type and location, patient-controlled intravenous analgesia usage, consumption of general anesthetics and pain rescue medications, as well as complications.The administration of dexmedetomidine resulted in decreased levels of inflammatory cytokines (interleukin-1 beta, interleukin-6, alongside tumor necrosis factor-alpha) and oxidative stress biomarkers (reactive oxygen species alongside malondialdehyde) but elevated levels of interleukin-10 and superoxide dismutase. In addition, the dexmedetomidine group showed lower postoperative numerical rating scale scores, reduced consumption of anesthetics, faster chest-tube removal, fewer patient-controlled intravenous analgesia presses, and shorter postoperative hospital stays.The administration of dexmedetomidine effectively attenuated surgical inflammation, oxidative stress, and postoperative pain, thereby promoting patient recovery after lung cancer surgery without increasing the risk of adverse effects or complications.Copyright © 2024 Elsevier Inc. All rights reserved.